The U.S. Food and Drug Administration (FDA) granted its first emergency use authorization (EUA) for a blood purification system to treat patients at risk for respiratory failure due to COVID-19. The authorization was granted to Terumo BCT Inc. and Marker Therapeutics, authorizing the use of their Spectra Optia Apheresis System and Depuro D2000 Absorption Cartridge devices to filter cytokines and other inflammatory proteins’ blood.
Death by Cytokine Storm Must be Stopped
Many of the deaths from COVID-19 occur from the so-called ‘Cytokine Storm’—an incredibly dangerous situation that appears to be a trademark of SARS-CoV-2. In a horrific ending, COVID-19 patients are dying in isolation—with no family members allowed nearing them. With failing lungs (and other organs) patients last grasp for air terminates. This kind of horror has been faced by too many thousands of people around the world—and must be put to an end.
A New Device
Hence the new device. Its device is limited to the use of patients 18 or older that admitted to an intensive care unit with confirmed or imminent respiratory failure. The EUA specifies that the devices should only be used for patients with early a...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).